Literature DB >> 15238453

Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China.

Jiang He1, Dongfeng Gu, Kristi Reynolds, Xigui Wu, Paul Muntner, Jiangong Zhao, Jing Chen, Donghai Liu, Jingping Mo, Paul K Whelton.   

Abstract

BACKGROUND: Cardiovascular disease has become the leading cause of death in China. We examined the levels of serum total and lipoprotein cholesterol and status of awareness, treatment, and control of hypercholesterolemia in China. METHODS AND
RESULTS: A cross-sectional survey in a nationally representative sample of 15,540 Chinese adults 35 to 74 years of age was conducted during 2000 to 2001. Serum cholesterol was measured by use of standard methods, and information on treatment of hyperlipidemia was obtained by use of a standard questionnaire. Age-standardized mean levels of total, HDL, and LDL cholesterol and triglycerides were 186.1, 51.7, 109.5, and 128.1 mg/dL, respectively. Of the Chinese population 35 to 74 years of age, 23.8% (112,500000 persons) had borderline high total cholesterol (200 to 239 mg/dL), and 9.0% (42,540000 persons) had high total cholesterol (> or =240 mg/dL). The population estimates for borderline high (130 to 159 mg/dL), high (160 to 189 mg/dL), and very high (> or =190 mg/dL) LDL cholesterol were 17.0% (80,122000 persons), 5.1% (24,329000 persons), and 2.7% (12,822000 persons), respectively. In addition, 19.2%, or 90 803 000 persons, had a low HDL cholesterol (<40 mg/dL). Among those who had a total cholesterol > or =200 mg/dL or who were on cholesterol-lowering medications, the proportion of men and women who were aware, treated, and controlled was only 8.8% and 7.5%, 3.5% and 3.4%, and 1.9% and 1.5%, respectively.
CONCLUSIONS: The prevalence of hypercholesterolemia was relatively high and the percentage of adults with controlled blood cholesterol was low in China. Prevention and treatment of hypercholesterolemia should be an important component of a national strategy to reduce the substantial and increasing burden of cardiovascular disease in China.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238453     DOI: 10.1161/01.CIR.0000136583.52681.0D

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  56 in total

1.  Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china.

Authors:  Andrew Moran; Dongfeng Gu; Dong Zhao; Pamela Coxson; Y Claire Wang; Chung-Shiuan Chen; Jing Liu; Jun Cheng; Kirsten Bibbins-Domingo; Yu-Ming Shen; Jiang He; Lee Goldman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-05-04

2.  Risk factors for noncommunicable chronic diseases in women in China: surveillance efforts.

Authors:  Yichong Li; Limin Wang; Yong Jiang; Mei Zhang; Linhong Wang
Journal:  Bull World Health Organ       Date:  2013-09-01       Impact factor: 9.408

3.  The Management of LDL Cholesterol and Predictors of Goal Achievement in Stroke Patients in China: A Cross-Sectional Study.

Authors:  Chun-Juan Wang; Yi-Long Wang; Zi-Xiao Li; Yong-Jun Wang
Journal:  CNS Neurosci Ther       Date:  2016-07       Impact factor: 5.243

4.  Cholesterol and cardiovascular disease in the elderly. Facts and gaps.

Authors:  Francisco J Félix-Redondo; Maria Grau; Daniel Fernández-Bergés
Journal:  Aging Dis       Date:  2013-03-01       Impact factor: 6.745

5.  Nutritional status of the elderly in rural North China: a cross-sectional study.

Authors:  W Zhang; Y Li; T D Wang; H-X Meng; G-W Min; Y-L Fang; X-Y Niu; L-S Ma; J-H Guo; J Zhang; M-Z Sun; C-X Li
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

6.  Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study.

Authors:  Soneil Guptha; Rajeev Gupta; Prakash Deedwania; Anil Bhansali; Anuj Maheshwari; Arvind Gupta; Balkishan Gupta; Banshi Saboo; Jitendra Singh; Vijay Achari; Krishna Kumar Sharma
Journal:  Indian Heart J       Date:  2014-04-16

7.  Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Orhan Deger; Mustafa Kocak; Murat Topbas
Journal:  Endocrine       Date:  2008-11-12       Impact factor: 3.633

8.  Dyslipidemia and eye diseases in the adult Chinese population: the Beijing eye study.

Authors:  Shuang Wang; Liang Xu; Jost B Jonas; Qi Sheng You; Ya Xing Wang; Hua Yang
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

9.  The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China.

Authors:  Andrew Moran; Dong Zhao; Dongfeng Gu; Pamela Coxson; Chung-Shiuan Chen; Jun Cheng; Jing Liu; Jiang He; Lee Goldman
Journal:  BMC Public Health       Date:  2008-11-27       Impact factor: 3.295

Review 10.  Outcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set.

Authors:  Geng Li; Ruxue Han; Wencong Cao; Zehuai Wen; Xiankun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-10       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.